<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442364</url>
  </required_header>
  <id_info>
    <org_study_id>VAP.VV012</org_study_id>
    <nct_id>NCT00442364</nct_id>
  </id_info>
  <brief_title>Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt</brief_title>
  <acronym>MRI</acronym>
  <official_title>An Open Label Multicenter Safety Study of the Varisolve® Procedure for the Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of the Varisolve® procedure in patients
      with right-to-left cardiac shunt (a defect in the heart).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Varicose veins are extremely common, affecting up to 25% of the western adult population.
      While in their early stages they are little more than a sometimes-painful aesthetic problem,
      progression is inevitable and some will progress to more severe and largely irreversible
      problems of chronic venous insufficiency (CVI) and, finally, venous leg ulcer. At present, no
      system has been proven to identify those that will progress and while varicose veins are not
      the only cause of CVI, in approximately 50% of patients with leg ulcers, superficial varicose
      veins are the only causal factor identified. The cost of management of simple varicose veins
      is relatively small in comparison with the long-term management of CVI and leg ulcers. Many
      patients progress to develop leg ulcers without having received primary treatment for their
      varicose veins.

      The current management of major varicose veins includes maintenance by compression stockings,
      injection sclerotherapy with liquid sclerosants, and superficial vein surgery. The
      disadvantages to surgery include the use of general anesthesia, incisions resulting in
      possible scars, a painful recovery period with significant functional down time and
      historically high rates of recurrence. Sclerotherapy has been performed since 1851 with the
      advent of hypodermic needles. The two surfactant sclerosants most widely used are sodium
      tetradecyl sulphate (STS, STD®, Sotradecol or Fibro-vein) and polidocanol (Macrogol 400 Ph
      Eur, Aethoxyskerol®). Sotradecol is the only FDA-approved sclerosant. With the advent of
      duplex ultrasound scanning, the technique of echo-guided sclerotherapy has widened the
      possibilities for sclerotherapy of large veins but the liquid sclerosants available are
      rapidly deactivated and diluted by blood frequently resulting in unsatisfactory outcomes.
      Because the microfoam delivers sclerosant more efficiently to the venous endothelium, it is
      believed that lower concentrations of polidocanol (Varisolve)can be used when compared with
      liquid sclerosant. BTG International Ltd is developing sclerosant microfoam technology based
      on polidocanol (PD)(Varisolve) into a pharmaceutical product.

      The presence of bubbles in the heart has been a concern as bubbles may pass from the right
      heart to the left through a patent foramen ovale (PFO) or other right-to-left shunt. Once in
      the systemic circulation, some bubbles inevitably pass into the cerebral circulation where
      their theoretical potential for causing damage due to occlusion of vessels is recognized yet
      ill defined.

      Therefore this study is to determine whether patients with bubbles detected in the middle
      cerebral artery (MCA) during the Varisolve® procedure experience any sub-clinical,
      safety-related events such as abnormalities on brain MRI, neurological examination, cardiac
      markers or other symptoms or signs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects</measure>
    <time_frame>28 day followup</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polidocanol (1%) Microfoam (Varisolve)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polidocanol (1%) Microfoam (Varisolve)</intervention_name>
    <description>Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endovenous Microfoam Occlusion</intervention_name>
    <description>Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18 to 60 with severe varicose veins, CEAP classes 3, 4 and 5
             (CEAP is a classification and grading system for chronic venous disease)

          -  Saphenofemoral junction (SFJ) incompetence. Retrograde blood flow in the GSV, greater
             than or equal to 1.0 second demonstrated by duplex scanning.

          -  Normal MRI, as assessed on MRI examination performed within 5 days prior to procedure.

          -  Patient must be willing and able to participate in the study and provide written
             informed consent.

        Exclusion Criteria:

          -  Presence of venous ulcers (i.e. CEAP classification C6) or local infection in the limb
             to be treated.

          -  Incompetence of the small saphenous vein (SSV) in the leg to be treated. Venographic
             or ultrasonographic evidence of current or previous deep vein thrombosis (DVT) (see
             Appendix IV).

          -  Deep venous occlusion and/or incompetence. Evidence of deep venous reflux is
             acceptable if it is confined to a limited segment caused by filling of the incompetent
             superficial system through a perforator or the SFJ.

          -  Patients with known atherosclerotic disease or presence of major risk factors,
             including LDL cholesterol greater than 130 mg/dl, blood pressure greater than 140 mmHg
             systolic or 90 mmHg diastolic, or diabetes requiring treatment with oral hypoglycemic
             drugs or insulin.

          -  Smokers.

          -  History suggestive of cerebral atherosclerosis, transient ischemic attack (TIA),
             stroke, presence of carotid bruit or history of abnormal carotid duplex examination.

          -  Clinically significant dilated cardiomyopathy, evidence of regional wall motion
             abnormalities suggestive of prior myocardial infarction, rheumatic mitral valve
             disease, moderately severe or worsening cardiac valvular disease (&gt; 2+ on a scale of
             4), known or suspected congenital heart disease, evidence of right sided volume or
             pressure overload, history of atrial fibrillation. Patients with PFO, atrial septal
             defect, or other right-to-left shunt are not excluded unless associated with other
             abnormalities as above.

          -  Peripheral vascular disease.

          -  Spontaneous emboli seen on TCD prior to contrast injection.

          -  Body Mass Index &gt;30.0.

          -  Recent or current upper respiratory tract illness or other cause of increased
             coughing.

          -  Arterial insufficiency in the leg to be treated (ankle: brachial pressure ratio less
             than 0.9).

          -  Reduced mobility - unable to maintain a brisk walk unaided for a minimum of 5 minutes
             per hour per day.

          -  Prolonged automobile or air travel (&gt;4 hours) 1 month prior to treatment, or planned
             within 1 month of proposed treatment.

          -  Current or prior pulmonary embolism.

          -  Major surgery, prolonged hospitalization or pregnancy within 3 months of screening.

          -  Hormone replacement therapy or hormonal contraception (oral or dermal patch).

          -  Current or recent (&lt;7 days before treatment) aldehyde dehydrogenase inhibitor therapy,
             e.g. disulfiram, or other drugs with similar reactions to alcohol (metronidazole,
             tinidazole).

          -  Current anticoagulation therapy.

          -  Inability to identify a unilateral or bilateral temporal bone window and middle
             cerebral artery signal by transcranial Doppler ultrasound.

          -  Inability to undergo magnetic resonance imaging of the brain

          -  Participation in a clinical study involving an unlicensed pharmaceutical product
             within the 3 months of screening.

          -  Previous enrollment in this study.

          -  Major co-existing disease (e.g. malignancy, pulmonary disease, renal or hepatic
             insufficiency).

          -  Known allergic response to polidocanol or severe and multiple allergic reactions.

          -  Women of childbearing potential not using effective contraception

          -  Pregnant or lactating women.

          -  Current alcohol or drug abuse.

          -  Clinically significant laboratory abnormalities in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Rush, MD</last_name>
    <role>Study Director</role>
    <affiliation>BTG International Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2007</study_first_submitted>
  <study_first_submitted_qc>February 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2007</study_first_posted>
  <results_first_submitted>January 7, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2014</results_first_posted>
  <disposition_first_submitted>September 14, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>September 14, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 21, 2011</disposition_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PFO</keyword>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>Right-to-Left Shunt</keyword>
  <keyword>Sclerotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polidocanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Polidocanol 1% Injectable Microfoam</title>
          <description>polidocanol injectable microfoam 1%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with bubbles detected on MRI</population>
      <group_list>
        <group group_id="B1">
          <title>Safety Evaluable</title>
          <description>patients treated with polidocanol 1% injectable foam with circulating bubbles present on MRI</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.6" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects</title>
        <time_frame>28 day followup</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Evaluable Population</title>
            <description>polidocanol injectable foam 1% with circulating MCA bubbles present at MRI</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Circulating MCA Bubbles Present on MRI Who Had Signficant Clinical or Neurological Effects</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Safety Evaluable</title>
          <description>patients treated with polidocanol 1% injectable foam with circulating bubbles present on MRI</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extrermity</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>limb discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hematoma evacuation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>ecchymosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David DI Wright MB BS</name_or_title>
      <organization>BTG International Inc</organization>
      <phone>610-278-1660</phone>
      <email>david.wright@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

